We mustn’t make a correlation-causation error by assuming that the new registration requirements necessarily caused the decrease in positive findings – maybe other things changed in that same year, like a shift in focus to different kinds of treatments. But it’s plausible to think that the public pre-registration of their plans might have led the clinical triallists to be more transparent and honest about what they found.
